| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
J Clin Oncol
|
2013
|
3.65
|
|
2
|
Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients.
|
Cancer
|
2004
|
3.07
|
|
3
|
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.
|
J Clin Oncol
|
2012
|
2.94
|
|
4
|
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
2.81
|
|
5
|
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
|
J Clin Oncol
|
2005
|
2.62
|
|
6
|
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
|
J Clin Oncol
|
2011
|
2.40
|
|
7
|
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
|
Haematologica
|
2008
|
2.26
|
|
8
|
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
|
Cancer
|
2003
|
2.21
|
|
9
|
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.
|
J Clin Oncol
|
2009
|
2.19
|
|
10
|
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
|
Br J Haematol
|
2010
|
1.85
|
|
11
|
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
|
J Clin Oncol
|
2003
|
1.70
|
|
12
|
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.
|
Blood
|
2009
|
1.62
|
|
13
|
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
|
J Clin Oncol
|
2006
|
1.60
|
|
14
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
15
|
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
|
J Clin Oncol
|
2012
|
1.56
|
|
16
|
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
|
Cancer
|
2007
|
1.47
|
|
17
|
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
|
J Clin Oncol
|
2005
|
1.42
|
|
18
|
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study).
|
Leuk Lymphoma
|
2014
|
1.40
|
|
19
|
Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.40
|
|
20
|
Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
|
J Clin Oncol
|
2010
|
1.36
|
|
21
|
International prognostic index-based outcomes for diffuse large B-cell lymphomas.
|
Cancer
|
2002
|
1.36
|
|
22
|
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
|
J Hematol Oncol
|
2014
|
1.34
|
|
23
|
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation.
|
J Clin Oncol
|
2004
|
1.28
|
|
24
|
Non-Hodgkin's lymphomas, version 1.2013.
|
J Natl Compr Canc Netw
|
2013
|
1.20
|
|
25
|
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
|
Blood
|
2012
|
1.19
|
|
26
|
Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature.
|
Am J Hematol
|
2007
|
1.17
|
|
27
|
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
|
J Clin Oncol
|
2009
|
1.16
|
|
28
|
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2007
|
1.10
|
|
29
|
Non-Hodgkin's lymphomas.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
30
|
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
|
Clin Cancer Res
|
2004
|
1.05
|
|
31
|
Non-Hodgkin's Lymphomas, version 3.2012.
|
J Natl Compr Canc Netw
|
2012
|
1.03
|
|
32
|
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
|
Cancer
|
2008
|
1.01
|
|
33
|
Meta-analyses of the association between Chlamydia psittaci and ocular adnexal lymphoma and the response of ocular adnexal lymphoma to antibiotics.
|
Cancer
|
2007
|
1.01
|
|
34
|
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
|
Br J Haematol
|
2010
|
1.00
|
|
35
|
Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular adnexal lymphoma.
|
Arch Ophthalmol
|
2007
|
0.99
|
|
36
|
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
|
J Infect Dis
|
2006
|
0.97
|
|
37
|
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
|
Clin Cancer Res
|
2013
|
0.96
|
|
38
|
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2004
|
0.95
|
|
39
|
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2003
|
0.93
|
|
40
|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
|
Br J Haematol
|
2011
|
0.92
|
|
41
|
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
|
Eur J Cancer
|
2006
|
0.91
|
|
42
|
CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.
|
J Am Acad Dermatol
|
2008
|
0.90
|
|
43
|
Hodgkin lymphoma.
|
J Natl Compr Canc Netw
|
2011
|
0.88
|
|
44
|
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
|
Blood
|
2006
|
0.87
|
|
45
|
Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy.
|
Ophthalmic Surg Lasers Imaging
|
2007
|
0.87
|
|
46
|
Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
|
Cancer
|
2005
|
0.87
|
|
47
|
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
|
Cancer
|
2007
|
0.87
|
|
48
|
Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
|
Ophthal Plast Reconstr Surg
|
2010
|
0.87
|
|
49
|
Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.
|
Cancer
|
2011
|
0.86
|
|
50
|
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2007
|
0.84
|
|
51
|
Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas.
|
Leuk Lymphoma
|
2002
|
0.83
|
|
52
|
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas.
|
Br J Haematol
|
2013
|
0.82
|
|
53
|
Central nervous system prophylaxis in peripheral T-cell lymphoma.
|
Blood
|
2010
|
0.82
|
|
54
|
Peripheral T-cell lymphomas: a review of current approaches and hopes for the future.
|
Front Oncol
|
2013
|
0.82
|
|
55
|
Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma.
|
Expert Rev Hematol
|
2013
|
0.82
|
|
56
|
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.82
|
|
57
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
J Clin Oncol
|
2009
|
0.81
|
|
58
|
Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
|
Cancer
|
2003
|
0.81
|
|
59
|
Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study).
|
Br J Haematol
|
2014
|
0.79
|
|
60
|
Hepatosplenic T-cell lymphoma and TNF-α inhibitors.
|
Expert Rev Hematol
|
2009
|
0.78
|
|
61
|
Hepatosplenic gamma-delta T-cell lymphoma, disseminated intravascular coagulation, and systemic mastocytosis: an unusual presentation for a rare disease.
|
Clin Adv Hematol Oncol
|
2010
|
0.78
|
|
62
|
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
|
Br J Haematol
|
2014
|
0.78
|
|
63
|
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
|
Br J Haematol
|
2013
|
0.77
|
|
64
|
Marginal zone lymphomas: factors that affect the final outcome.
|
Cancer
|
2010
|
0.76
|
|
65
|
Targeting CD30 in anaplastic large cell lymphoma.
|
Curr Hematol Malig Rep
|
2012
|
0.76
|
|
66
|
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.
|
Cancer
|
2013
|
0.76
|
|
67
|
Racial differences in chronic lymphocytic leukemia. Digging deeper.
|
Cancer
|
2013
|
0.76
|
|
68
|
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
|
Oncol Rep
|
2003
|
0.75
|
|
69
|
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.75
|
|
70
|
Current treatment of peripheral T-cell lymphoma.
|
Clin Adv Hematol Oncol
|
2011
|
0.75
|
|
71
|
Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
|
Curr Treat Options Oncol
|
2015
|
0.75
|
|
72
|
Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma.
|
Cancer J
|
2003
|
0.75
|
|
73
|
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
|
Br J Haematol
|
2014
|
0.75
|
|
74
|
The lymphomas: molecular pathways and novel therapeutic targets.
|
Curr Hematol Rep
|
2005
|
0.75
|
|
75
|
Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach.
|
Clin Adv Hematol Oncol
|
2010
|
0.75
|
|
76
|
Second-line 90Yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab.
|
Ophthal Plast Reconstr Surg
|
2012
|
0.75
|